Systolic anterior motion of mitral valve leaflet following accessory pathway ablation in a patient without hypertrophic cardiomyopathy: a case report Authors: Xuze Lin, Xixing Wang, Qiang Li, Fanqi Meng, Jinzan Cai Published: 2026 ABSTRACT AbstractBackgroundAccessory pathway ablation is recommended for patients with symptomatic Wolff–Parkinson–White (WPW) syndrome. Although elimination of the accessory pathway restores normal ventricular activation and improves synchrony, it can occasionally cause systolic anterior motion (SAM) of the mitral valve leaflet, which can lead to functional left ventricular outflow tract (LVOT) obstruction.Case summaryWe report a case of a patient admitted with WPW syndrome. After successful posteroseptal accessory pathway ablation, the patient developed exertional chest tightness and syncope. Echocardiography revealed significant SAM of the mitral valve leaflet and an elevated LVOT peak pressure gradient. Cardiac magnetic resonance confirmed a sigmoid-shaped interventricular septum and a small left ventricular cavity. Genetic testing excluded pathogenic mutations in genes associated with hypertrophic cardiomyopathy. Treatment with metoprolol alleviated his symptoms, with no recurrence of syncope. Follow-up echocardiography showed that the SAM of the mitral valve leaflet had been resolved.ConclusionAlthough SAM of the mitral valve leaflet rarely occurs following accessory ablation, it could induce deleterious consequences. We hypothesized that the coexistence of a sigmoid septum and a small ventricular cavity may increase the risk for functional outflow tract obstruction after accessory pathway ablation. Accessory pathway ablation can result in functional obstruction of left ventricular outflow tract (LVOT), even in patients without hypertrophic cardiomyopathy. Accessory pathway ablation can result in functional obstruction of left ventricular outflow tract (LVOT), even in patients without hypertrophic cardiomyopathy. Coexistence of a sigmoid septum and a small ventricular cavity may increase the risk for functional LVOT obstruction after accessory pathway ablation. Coexistence of a sigmoid septum and a small ventricular cavity may increase the risk for functional LVOT obstruction after accessory pathway ablation. Long-term β-blocker therapy ameliorates functional LVOT obstruction following accessory pathway ablation. Long-term β-blocker therapy ameliorates functional LVOT obstruction following accessory pathway ablation. Introduction Wolff–Parkinson–White (WPW) syndrome is a disorder characterized by the presence of an overt accessory pathway that predisposes patients to tachyarrhythmia and sudden death. Catheter ablation remains the standard treatment for patients with symptomatic WPW syndrome.1 Previous research has established that accessory pathway ablation improves cardiac function by restoring ventricular synchrony.2 However, no study has yet reported on the development of left ventricular outflow tract (LVOT) obstruction among patients without hypertrophic cardiomyopathy (HCM) who had undergone this procedure. Summary figure Case presentation In March 2017, a 57-year-old man was admitted to our cardiology centre with a 9-year history of recurrent palpitations. The episodes were sudden onset and self-terminating, each lasting 1–2 min, with no correlation to physical exertion. The patient denied chest pain, chest tightness, syncope, or presyncope and had no significant family history of sudden unexplained death or cardiac disease. His vital signs were stable, with blood pressure ranging from 110 to 130/60 to 80 mmHg. Cardiac auscultation revealed no abnormal heart sounds or murmurs. His exercise tolerance was good, corresponding to New York Heart Association functional Class I. Physical examination for limb mobility or neuromuscular deficits yielded unremarkable results. He had no active medications, no history of smoking, no known allergies, and no exposure to toxins or radiation. Based on the characteristics of the palpitations, potential differential diagnoses included tachyarrhythmias, particularly those mediated by re-entry mechanisms, as well as premature ventricular contractions, myocardial ischaemia related to coronary artery disease, and functional cardiac symptoms. His 12-lead electrocardiogram (ECG) showed sinus rhythm with ventricular pre-excitation, and a negative delta wave in the initial QRS in the V1 lead was indicated (Figure 1A). Transthoracic echocardiography (Figure 2A–E) revealed the following: an interventricular septum (IVS) of 12.6 mm, a left ventricular posterior wall of 8.5 mm, and normal appearance of all other cardiac structures with preserved ejection fraction (71%). The 24-hour Holter monitoring revealed a sinus rhythm throughout the recording, with 4 atrial premature contractions and 21 ventricular premature contractions. N-terminal pro-B-type natriuretic (NT-proBNP, 62.93 pg/mL) and high-sensitivity troponin T (hs-TnT, 8.78 pg/mL) levels were within the normal limits. The 12-lead electrocardiography performed at different timepoints. Transthoracic echocardiography performed at different timepoints. (A–E) Preoperative echocardiography showing no systolic anterior motion (SAM) of the mitral valve (March 2017, 1 day before ablation). (F–G) M-mode echocardiography in the outflow tract view indicating SAM of the mitral valve (April 2017, 1 month after ablation). (H) Outflow tract view showing significant SAM of the mitral valve (arrow) (April 2017, 1 month after ablation). (I, J) Doppler image suggesting elevation of the left ventricular outflow tract (LVOT) maximum flow velocity (Vp) and peak pressure gradient (PPG) (April 2017, 1 month after ablation). (K–O) Echocardiography indicating resolution of the mitral valve SAM and reduction of the LVOT-Vp and LVOT-PPG (October 2019, 2 years after ablation). The patient subsequently underwent an electrophysiology study to confirm the location of atrioventricular accessory pathway (Figure 3A). The results confirmed a retrograde-conducting accessory atrioventricular pathway at the left posterior septum, with inducible orthodromic atrioventricular re-entrant tachycardia (Figure 3B). After successful ablation of the accessory pathway, the patient’s 12-lead ECG showed resolution of ventricular pre-excitation (Figure 1B). The patient reported no complaints after the ablation and was discharged from hospital 2 days later. His NT-proBNP remained mildly elevated after ablation (150 pg/mL). Electrophysiology study results. Note that His bundle electrodes were not enabled. (A) Electrophysiology study showing sinus rhythm with ventricular pre-excitation. Atrioventricular bypass tract was estimated to be located at the CS7,8 region. (B) Atrioventricular re-entrant tachycardia (AVRT) was induced by premature atrial contraction, with the earliest retrograde conduction wave detected at CS7,8. The electrophysiology study confirmed the presence of an atrioventricular accessory pathway located at the left posterior septum with retrograde conduction capability, and the pathway was able to induce AVRT. ABL, ablation tip electrode; CS, coronary sinus electrode; PVC, premature ventricular contraction; S, sinus rhythm. Around 1 month after discharge, the patient returned to the outpatient clinic due to exertional chest tightness and an episode of syncope. Neurological examination revealed no positive findings, although a systolic murmur could be heard on auscultation over the left third to fourth intercostal spaces. Echocardiography revealed thickening of IVS (14.2 mm) and significant systolic anterior motion (SAM) of mitral valve leaflet in rest (Figure 2F–J). His 12-lead ECG showed similar results to the previous one (Figure 1C). The 24-hour Holter monitoring did not reveal any bradycardia, tachycardia, or prolonged R–R interval. Blood pressure monitoring for 24 h did not show systolic or diastolic blood pressure abnormalities. Moreover, his plasma D-dimer levels and thyroid function indicators were normal, which excluded thrombosis-related disease or thyroid dysfunction. The patient subsequently underwent coronary angiography, which revealed no obstructive lesion in artery lumen. Although concomitant cardiac catheterization with pressure monitoring was planned during angiography, the patient declined for financial reasons. Considering the septal thickening and SAM of mitral valve leaflet, we recommended adding 47.5 mg of metoprolol tartrate per day. After 2 weeks of administration, the patient reported no drug-related adverse reactions, for which the dosage of metoprolol tartrate was subsequently increased to 95 mg per day. During the subsequent follow-up, the patient reported no chest tightness or syncope. After 1 year of metoprolol administration, electrocardiography and echocardiography were performed. The 12-lead ECG showed no obvious changes compared to that acquired before (Figure 1D). Echocardiography indicated slight SAM of mitral valve leaflet in rest (see Supplementary material online, Figure S1A–E). Moreover, the LVOT peak pressure gradient (PPG), LVOT maximum flow velocity (Vp), and IVS thickness were all reduced. No systolic heart murmurs were detected. The patient underwent another echocardiography 1 year later, which showed complete resolution of mitral valve SAM at rest (Figure 2K–O). Exercise stress echocardiography showed no evidence of mitral valve SAM during both the exercise and recovery phases (Table 1). Table 1Exercise stress echocardiography performed in October 2019 (2 years after ablation). The exercise test was terminated prematurely due to lower limb fatigue, and the target heart rate was not attained (131 bpm)HR (bpm)BP (mmHg)SpO2 (%)Vp-LVOT (m/s)PPG-LVOT (mmHg)SAM of mitral valveBaseline68119/70981.37—Stress stage 189145/65991.59—Stress stage 2104143/58991.610—Stress stage 3110160/56992.015—Recovery stage 1101159/61991.914—Recovery stage 294152/62991.812— Exercise stress echocardiography performed in October 2019 (2 years after ablation). The exercise test was terminated prematurely due to lower limb fatigue, and the target heart rate was not attained (131 bpm) Given that the patient had mild ventricular septal thickening (>13 mm), genetic testing was subsequently performed according to guideline recommendations to determine the presence of genetic mutations associated with HCM.3 Accordingly, the results of whole-exome sequencing excluded the presence of any pathogenic or likely pathogenic variant of sarcomere gene (see Supplementary material online, Table S1). Furthermore, results of late gadolinium enhancement cardiac magnetic resonance imaging (CMRI) showed no obvious myocardial fibrosis but did reveal a sigmoid-shaped IVS and a small left ventricular cavity4 (Figure 4A–G). Cardiac magnetic resonance imaging (CMRI) performed in January 2021. (A–C). Cine sequence images showing a sigmoid-shaped interventricular septum (IVS) (arrow). (D–F) Late gadolinium enhancement images showing no obvious fibrosis in the myocardium. Sigmoid-shaped IVS (arrow). (G) Parameters assessed via CMRI. Body surface area was calculated according to the Du Bois formula. An 8-year follow-up with this patient after initiating metoprolol showed that the patient had not experienced any syncope or exertional chest tightness. Discussion Asymmetric septal hypertrophy, which has been closely associated with HCM, frequently causes narrowing of LVOT area and elevated LVOT velocity during cardiac contraction. Increased flow velocity through the narrowed LVOT could induce the Venturi effect, during which mitral valve may be sucked up into the outflow tract to create an obstruction. This phenomenon has been considered to be the primary cause of mitral valve SAM. Additionally, previous studies have indicated that mitral valve SAM may also occur in the absence of septal hypertrophy. In such cases, increased left ventricular ejection fraction (LVEF) values and decreased LVOT diameters had been often observed.5 An excessively high baseline LVEF may suggest a potential risk for a small ventricular cavity.6 In such patients, the absolute size of the LVOT was typically reduced. A sigmoid-shaped IVS has been considered as a variation in the contour of the left ventricular outlet.7 Previous autopsy studies have demonstrated that sigmoid septum progression is age-related and predominantly occurs in males.8 Although the precise definition of the sigmoid septum remains a subject of debate, the general consensus is that it represents an isolated septal thickening not secondary to other ventricular wall hypertrophy disorders. Among patients with a sigmoid septum, the basal septal bulge can cause a narrowing of the LVOT and contribute to the elevation of the LVOT velocity, which could occasionally cause significant symptoms.9–11 Evidence suggests that ablation of the accessory pathway can shorten the QRS duration and contribute to the synchronization of ventricular contraction, which further increased ventricular ejection function.2 The CMRI of this patient indicated a sigmoid-shaped IVS and small heart size, which could be the underlying cause of his symptoms. Besides, we observed increase of septal thickness after accessory pathway ablation, potentially due to ventricular systolic synchrony.12 We hypothesized that the improvement in left ventricular function after ablation, in the context of a sigmoid-shaped IVS and a small heart, increased the patient’s LVOT velocity and induced mitral valve SAM. The LVOT obstruction caused by a sigmoid-shaped IVS can be functional and reversible with β-blockers.11 β-Blockers ameliorate dynamic LVOT obstruction by reducing the heart rate, which improves ventricular filling, and attenuating myocardial contractility.13–15 This case highlights the importance of future large-scale studies to evaluate the impact of sigmoid septum geometry and outflow tract diameter on post-ablation haemodynamic changes. Conclusions The SAM of the mitral valve following accessory ablation is rare but could induce deleterious consequences in patients with WPW. Comprehensive preoperative examinations are therefore imperative, especially in those with a sigmoid-shaped IVS and high LVEF. β-Blockers can be useful for reversing functional LVOT obstruction. Lead author biography For image description, please refer to the figure legend and surrounding text.Xuze Lin is a cardiologist specializing in cardiovascular intervention, structural heart disease, and echocardiography, currently employed at Xiamen University Cardiovascular Hospital. Supplementary Material